摘要
目的探究新诊断2型糖尿病患者开展沙格列汀联合二甲双胍治疗的临床疗效及安全性,并为这类患者最优化诊疗服务积累循证经验。方法选取该院内分泌科2012年2月—2014年1月收治的94例新诊断2型糖尿病患者,利用随机数字表法进行分组,分别设为观察组和对照组,每组各47例。其中对照组给予阿卡波糖联合二甲双胍治疗方案,观察组给予沙格列汀联合二甲双胍治疗方案。记录二组患者治疗前后空腹血糖(FBG)、餐后2h血糖(2hPG)、糖化血红蛋白(HbA1c)、空腹胰岛素、胰岛素抵抗指数(HOMA-IR)、体重及体质指数,同时比较二组服药依从性情况及不良反应发生率。结果二组治疗前FBG、2hPG及HbA1c值差异无统计学意义(P>0.05);治疗后,观察组FBG、2hPG及HbA1c值均低于对照组,差异有统计学意义(P<0.05)。二组治疗前空腹胰岛素水平及HOMA-IR值差异无统计学意义(P>0.05);治疗后,观察组空腹胰岛素水平高于对照组(P<0.05),HOMA-IR值低于对照组(P<0.05)。二组治疗期间低血糖发生率差异无统计学意义(P>0.05);观察组HbA1c达标率高于对照组,差异有统计学意义(P<0.05)。二组治疗前后体重及体重指数差异无统计学意义(P>0.05)。观察组药物漏服率及错服率均低于对照组,差异有统计学意义(P<0.05)。结论二甲双胍配伍沙格列汀治疗2型糖尿病患者的临床疗效优于二甲双胍配伍阿卡波糖方案,且安全性尚佳,值得在临床上进一步推广。
Objective To explore the clinical efficacy and safety of newly diagnosed type 2 diabetes patients treated with sand sitagliptin and metformin, and accumulate evidence- based experience for this kind of pa- tients optimal treatment services. Methods The 94 patients with newly diagnosed methods in authors hos- pital from February 2012 to January 2014 in type 2 diabetic patients, using random number table method for grouping, they were divided into study group and control group, 47 cases in each group. The control group received acarbose and metformin treatment, the research group were treated by Shah Glenn Dean combined with metformin treatment. Fasting blood glucose {FBG）, 2h postprandial blood glucose （2hPG）, glycosylated hemoglobin （HbAlc）, fasting insulin, insulin resistance index （HOMA - IR）, body weight and body mass index of two groups were recorded before and after treatment, and medication compliance and adverse reaction rate were compared between the two groups. Results Before treatment, FBG, 2hPG and HbA1 c values had no significant difference （P〉0.05） between the two groups, and the fasting insulin level and HOMA-IR value also had no significant difference （P〉0. 05）. After treatment, FBG, 2hPG and HbAlc in study group were lower than that in the control group, but the fasting insulin levels were higher and the HOMA- IR value was lower, the difference was statistically significant （P〈0.05）. Hypo- glycemia rates of two groups during treatment were not statistically significant （P〉0.05） ; HbAlc stand ard rate was higher in the research group than that in the control group, the difference was statistically sig- nificant （P〈0.05）. Body weight and body mass index had no significant difference between the two groups before and after treatment （P〉0.05）. The medication mistakes and wrong of research group wear rate were lower than the control group, the difference was statistically significant （ P〈 0. 05）. Conclusion Clinical curative effect of metformin and Shah Glenn Dean therapy in patients with type 2 diabetes is better than metformin and aearbose schemes, and the security is good, worthy of further promotion in clinic.
出处
《中国煤炭工业医学杂志》
2015年第1期23-27,共5页
Chinese Journal of Coal Industry Medicine
关键词
2型糖尿病
沙格列汀
二甲双胍
降糖效果
不良反应
Type 2 diabetes mellitus
Shah Glenn Dean
Metformin
Hypoglycemic effect
Adverse reac- tion
